Evaluation of the Effect of Ondansetron as Additional Drug on Reducing Negative Symptoms in Hospitalized and Outpatient with Schizophrenia Disorders

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190321043096N1

Enrollment

Registered

2019-04-23

Start date

2019-04-09

Completion date

Unknown

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophernia. Schizophrenia, unspecified

Interventions

Intervention 1: Intervention group: This group receive risperidone as an antipsychotics. Besides that intervention group will receive andonestrone. The dose of ondansetron is 4 mg in the first week an

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: age of 18-65 No physical illness No alcohol or drug abuse The absence of pregnancy and lactation in women PANSS score of more than 15 Acceptance of written consent

Exclusion criteria

Exclusion criteria: Drug abuse or alcohol abuse Breastfeeding and pregnancy women The need for other psychotropic drugs during the study

Design outcomes

Primary

Measure	Time frame
Earn score 7-49 in the test of N-PANSs. Timepoint: Before starting the study and 6, 8 and 12 weeks after starting the study. Method of measurement: Based on DSM-5.	—

Secondary

Measure	Time frame
Negative symptoms of schizophrenia. Timepoint: Weeks of 0, 6, 8 and 12. Method of measurement: Evaluation Scale of PANSS.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHedye Mahmodi

Gorgan University of Medical Sciences

mitrajudy@goums.ac.ir+98 51 3605 7872

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026